Image

Defining Outcome Measures for Behavioural and Emotional Problems in Dystrophinopathies

Defining Outcome Measures for Behavioural and Emotional Problems in Dystrophinopathies

Recruiting
7-17 years
Male
Phase N/A

Powered by AI

Overview

Study aims to develop and to evaluate the neurophysiological and physiological response to a classical conditioning task.To better understand how Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) impacts mental health and how to assess it. Participants invited to complete questionnaires about behaviour, cognitive function and social interactions, complete computer tasks and have an optional MRI brain scan,

Description

The investigation aims to develop and to evaluate the neurophysiological and physiological response to a classical conditioning task, which is comparable to findings that have been made in the mdx dystrophic mouse (deficient in Dp427). The investigators will assess correlations between the specific DMD/BMD genotype and susceptibility to conditioning, as well as the relationship between conditioning and behavioural/emotional characteristics of the syndrome. At the end of the study, the objective is to deliver a comprehensive test battery that is suitable for use in a trial of AON delivery to improve brain function.

Eligibility

Inclusion Criteria:

  • DMD patients:
    1. Male
    2. Age range 7-17 years
    3. A genetically proven diagnosis of DMD.
    4. A genetic mutation that abrogates expression of Dp427 alone (assigned in DMD Group 1: Dp427-/Dp140+) or both Dp427 and Dp140 (assigned to DMD Group 2: Dp427-/Dp140-).
    5. Ability to consent/assent

BMD patients:

  1. Male
  2. Age range 7-17 years
  3. A genetically proven diagnosis of BMD.
  4. A genetic mutation that decreases expression of Dp427 alone (assigned to BMD Group 1), of both Dp427 and Dp140 (assigned to BMD Group 2).
  5. Ability to consent/assent

Control participants:

  1. Male
  2. Age range 7-17 years.
  3. Ability to consent/assent

Exclusion Criteria:

  • DMD & BMD patients:
    1. Significant visual or hearing impairment
    2. Specific phobias or sensory sensitivities to stimuli similar to the ones used in this study
    3. Current participation in a clinical trial investigating a new drug involved in dystrophin modulation.
    4. Inability to consent (for parents/guardians or self-reporting participants aged 16 and 17) or assent. This will exclude the rare individuals with extremely severe learning disability, as the assent in these patients is impossible (or the consent in self-reporting participants aged 16 and 17).

Control participants:

  1. Significant visual or hearing impairment
  2. Specific phobias or sensory sensitivities to stimuli similar to the ones used in this study
  3. Any diagnosis of neurological or psychiatric condition

General exclusion criteria for MRI:

  1. Claustrophobia
  2. Pacemakers and defibrillators
  3. Nerve stimulators
  4. Intracranial clips
  5. Intraorbital or intraocular metallic fragments
  6. Cochlear implants
  7. Ferromagnetic implants (e.g. thoracic implant for scoliosis)
  8. Inability to lie supine during less than 45 minutes
  9. Not having a general practitioner
  10. Severe learning disability which will require a general anaesthetic

Study details
    DMD
    BMD

NCT06581887

University College, London

21 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.